MBOT

Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across multiple sales territories Company experiencing increase in recurring customer orders, new accounts and growing pipeline of potential future accounts HINGHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it recorded revenue during its fiscal quarter ended March 31, 2026, benefiting from the Limited Market Release (LMR) of the LIBERTY System which took place during that period. Earlier this quarter, the Company commenced the Full Market Release (FMR) of the LIBERTY system, and revenue mid-way through the second quarter has already exceeded total first quarter revenue, driven by the number of accounts since the end of the LMR having more than doubled. Currently, hospitals in six states have adopted the LIBERTY system, including Georgia, Florida, New York, Michigan, Massachusetts, and North Carolina. Earlier this month, Boston (MA) became the first city and state in which the Company has multiple accounts using the LIBERTY system, which the Company believes reflects growing commercial momentum. This demonstrates that interest from physicians and hospitals is translating into new accounts across key sales territories, including two of the three sites that participated in the ACCESS-PVI pivotal clinical trial, which serves as a strong validation of the added value that it brings. Moreover, the breadth of the procedures that have been performed using the LIBERTY System includes what the Company believes is the world’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH), robotic Genicular Artery Embolization (GAE), a minimally invasive, non-surgical outpatient procedure designed to treat chronic knee pain, typically caused by osteoarthritis, robotic Y-90 radioembolization mapping and treatment for liver cancer, and others. “Our success during the first quarter was demonstrated across multiple metrics, including the continued progress of the limited market release leading to us commence the Full Market Release, the number of accounts that adopted the LIBERTY system and the users that deploye...

DENTSPLY SIRONA Inc. XRAY is scheduled to release first-quarter 2026 results on May 5, after market close. In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate by 3.57%. It delivered an average earnings surprise of 7.73% for the trailing four quarters. The Zacks Consensus Estimate for revenues is pegged at $840.1 million. The consensus mark for earnings is pinned at 28 cents per share. Our model estimates for revenues and adjusted earnings per share (EPS) are pinned at $846.2 million and 32 cents, respectively. DENTSPLY SIRONA’s first-quarter 2026 performance is likely have to reflected continued softness in the United States, along with lingering tariff-related pressures. The company remains in the early phase of executing its multi-year “Return-to-Growth” transformation plan, which is expected to weigh on near-term earnings due to elevated investments in innovation, commercial reorganization and clinical education. While these actions are aimed at restoring sustainable growth, they are likely to have kept margins under pressure in the to-be-reported quarter. Tariffs and softer demand trends in key categories like equipment, implants and CAD/CAM solutions are expected to continue in the U.S. market. Management also highlighted a headwind from dealer inventory adjustments, particularly tied to a shift toward a drop-ship model, with roughly $30 million of inventory expected to be worked down in the first half of 2026. These dynamics are likely to have weighed on volumes and revenue visibility in the quarter to be reported. From a segmental standpoint, ongoing weakness in Connected Technology Solutions, implants and orthodontics is likely to have persisted, given competitive pressures and lower procedural volumes. However, relatively stable trends in Essential Dental Solutions, along with continued strength in Wellspect Healthcare, may have provided some support. Distributor inventory levels for equipment and CAD/CAM remained below historical averages exiting 2025, indicating that any recovery is likely to be gradual and dependent on dealer reengagement efforts. On the geographic front, while the U.S. business is expected to have remained under pressure, international markets — particularly Europe — likely continued to demonstrate resilience. Management previously indicated stable end-market conditions outside the United Sta...

InnovAge INNV is scheduled to release third-quarter fiscal 2026 results on May 05, after market close. In the last reported quarter, the company delivered an earnings surprise of 100.00%. The company appears to have entered the second half of fiscal 2026 with strong operational momentum and improving financial visibility. While membership growth is likely to have remained solid, supported by successful Medicaid reinstatements and steady enrollment trends, some normalization is expected as prior tailwinds fade. At the same time, medical cost management and operational efficiencies are likely to have remained favorable, though seasonal pressures such as higher inpatient utilization could weigh modestly on margins. So far this year, INNV’s shares have surged 60.3% against the industry’s fall of 11.6%. The S&P Index has gained 6.5% in the same period. Image Source: Zacks Investment Research The Zacks Consensus Estimate for earnings is pegged at 6 cents per share, indicating an increase of 175% year over year. The consensus mark for revenues is pinned at $234.5 million, implying growth of 7.5% from the prior-year reported figure. InnovAge’s upcoming quarterly performance is likely to have reflected continued operational momentum, though some normalization in margins and seasonal pressures could temper near-term upside following a strong first half. The company recently delivered double-digit revenue growth and a sharp improvement in profitability, driven by better execution across its PACE (Program of All-Inclusive Care for the Elderly) model and favorable rate dynamics. At the consolidated level, revenue growth is expected to have remained healthy, supported by membership expansion and higher capitation rates. Recent strength has been aided by the successful reinstatement of participants who had previously lost Medicaid coverage, which boosted member months and reduced revenue reserves. However, as this tailwind normalizes, growth may increasingly depend on organic enrollment gains and retention improvements. Additionally, while Medicaid rates have been slightly favorable, the broader reimbursement environment remains subject to policy variability, particularly around Medicare risk adjustments. From a cost perspective, medical cost management has emerged as a key driver of margin expansion. The company has demonstrated improved control over inpatient and skilled...

Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. The study was performed at three leading medical centers in the U.S.; Memorial Sloan Kettering Cancer Center (New York, NY), Baptist Hospital of Miami (Miami, FL) and Brigham and Women’s Hospital (Boston, MA). The late-breaking podium presentation was given by Francois Cornelis, M.D., PhD, Director of the Neuro Vascular Interventional Radiology Program at Memorial Sloan Kettering Cancer Center. The data presented concluded that robotic endovascular procedures using LIBERTY® are feasible and significantly minimize radiation exposure. Significant Highlights of the ACCESS-PVI Study: Successful robotic navigation was achieved in every case (N=20), yielding a success rate of 100%, meeting the primary endpoint of the study. No Adverse Device Events (ADE=0%) were reported through the duration of follow-up. Mean difference in radiation exposure between operator and control was (-)29.8 µS, resulting in a mean 92% relative reduction in radiation exposure. Median robotic navigation time to target was 3 minutes. Participating physicians reported LIBERTY® performed as planned with a 100% satisfaction rate. “The ACCESS-PVI data and the performance of the system throughout the study reflect the hard work that the team has put into LIBERTY® over the past few years,” commented Harel Gadot, Chairman, CEO and President. “We are extremely pleased with the results in all aspects. As we shift focus to building our commercial capabilities and preparing for launch, we are confident that LIBERTY® will be well received in the market.” “We are very satisfied with the clinical data, as well as with the investigators’ feedback in terms of the short learning curve and intuitive operation of the device,” commented Dr. Juan Diaz-Cartelle, the Company’s Chief Medical Officer. “We are looking forward to working with interventional physicians and staff upon FDA’s clearance.” LIBERTY® is an investigational device pending FDA...